Table 1.

Baseline characteristics.

Characteristic	CENTAUR PB and TURSO group (n = 89)	PRO‐ACT external control group (n = 85)
Age a , b , years	57.9 (10.6), 31.0–79.0	57.2 (9.5), 33.8–75.6
Bulbar onset, n (%)	26 (29.2)	22 (25.9)
Riluzole use, n (%)	61 (68.5)	58 (68.2)
Pre‐baseline ALSFRS‐R slope a , points/month	0.96 (0.42), 0.12–1.94	0.91 (0.53), 0.12–3.03
VC a , b , percent predicted value	83 (19), 38 c –142	84 (13), 60–131
Baseline ALSFRS‐R total score	35.6 (5.73), 18.0–46.0	36.8 (5.35), 26.0–47.0
Time since ALS symptom onset a , months	13.6 (3.8), 3.0–20.0	13.0 (3.4), 4.1–17.6
Time since ALS diagnosis, months	5.9 (3.32), 1.3–15.7	5.2 (3.04), 0.5–14.1

Data are presented as mean (SD), range unless otherwise noted.

ALS, amyotrophic lateral sclerosis; ALSFRS‐R, Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised; PB and TURSO, sodium phenylbutyrate and taurursodiol; PRO‐ACT, Pooled Resource Open‐Access ALS Clinical Trials; SD, standard deviation; VC, vital capacity (forced or slow).

^a Denotes covariate used for propensity score matching.

^b At study baseline.

^c This represents the minimum value at baseline. All participants met VC criteria for trial inclusion at screening.